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Diabetes type-2 and the metabolic syndrome are prevalent in epidemic proportions and
result in significant co-morbid disease. Limitations in understanding of dietary effects and
cholesterol metabolism exist. Current methods to assess diabetes are essential, though
many are invasive; for example, blood glucose and lipid monitoring require regular finger
sticks and blood draws. A novel method to study these diseases may be non-invasive
breath testing of exhaled compounds. Currently, acetone and lipid peroxidation products
have been seen in small scale studies, though other compounds may be significant. As
Atlantic bottlenose dolphins (Tursiops truncatus) have been proposed as a good model for
human diabetes, applications of dietary manipulations and breath testing in this population
may shed important light on how to design human clinical studies. In addition, ongoing
studies indicate that breath testing in dolphins is feasible, humane, and yields relevant
metabolites. By studying the metabolic and cholesterol responses of dolphins to dietary
modifications, researchers may gain insight into human diabetes, improve the design of
costly human clinical trials, and potentially discover biomarkers for non-invasive breath
monitoring.
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Diabetes mellitus is a chronic human disease with large economic
and medical impact. A median of 8.2% of the US population has
type-2 diabetes (DM2), which is thought to develop from a com-
plex interplay between genetics, diet, obesity, and potentially other
common illnesses such as obstructive sleep apnea (1–5). Often
diabetes develops in humans together with elevated triglycerides.
In fact, the combination of abdominal obesity, lipid abnormali-
ties (e.g., low HDL and/or elevated triglycerides), elevated blood
pressure, and/or abnormal fasting glucose levels that do not reach
the diagnostic levels for DM2 constitute the metabolic syndrome
(MetS) (6, 7), though exact definitions and prevalence estimates of
the MetS vary according to published guidelines (8–11). It is use-
ful to think of the MetS and diabetes as existing along a spectrum,
and both are directly related to the development of cardiovascu-
lar disease. Diabetes care is estimated to comprise up to 14% of
gross US healthcare expenditures (1), and much of this cost is
driven by complications of DM2 including cardiovascular disease,
stroke, kidney disease, retinopathy, and foot ulcers (12). DM2 and
the MetS have reached epidemic proportions and without timely
interventions, costs and morbidity are expected to rise (13).
Though an abundance of human clinical data regarding DM2
exists to guide therapy, much of the understanding of how ther-
apies work remains elusive. For example, recent attention has
focused on dietary effects on DM2 and the MetS. It is known that
Mediterranean diets (i.e., those rich in monounsaturated fats such
as olive oil, legumes, lean meats, and vegetables) may improve
insulin sensitivity, obesity, cholesterol regulation, and glycemic
control, among other measures (14–16). The antioxidants found in
olive oil may have anti-inflammatory and anti-hypertensive effects
(17), however, no single component of the Mediterranean diet
studied in isolation has shown similar outcomes as the diet as
a whole. Moreover, many of the studies looking at the Mediter-
ranean diet differ in their composition making generalization of
the diet problematic. Other diets, such as low-carbohydrate and
low-fat, have also been studied in regard to their impacts on com-
ponents of DM2 and the MetS with variable results (18). Clearly,
an improved understanding of diet is important as one would
expect dietary interventions to be among the most cost-effective
ways to control DM2 and the MetS.
In addition to the problem of understanding therapeutic inter-
ventions in DM2 and the MetS, current monitoring of these
complex diseases requires, in part, invasive blood testing to assess
glucose and lipids. One novel and emerging method of research
which may benefit several lines of human clinical investigation,
including to the study of DM2 and the MetS, is exhaled breath
analysis. Exhaled breath analysis has been used for centuries in
human disease. For example, volatile ketones resulting from the
lipolysis of adipocytes when insulin production is diminished
(e.g., type I diabetes) or in starvation states can be smelled on
the breath as a sweet, fruity odor (19). More recent medical uses of
exhaled breath include cancer detection, lung diseases, aging, and
gastrointestinal disorders, to name a few (20, 21).
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EXHALED BREATH FOR MetS AND DM2 MONITORING
Exhaled breath is collected as an ambient gas or liquid [exhaled
breath condensate (EBC)] using non-invasive collection systems
that cool expired breath, and both of these fractions contain
interesting metabolites. The advantage of analyzing the gaseous
fraction is the identification of volatile compounds which may
be conducted in real-time. Such volatile compounds are likely
representative of end-points of metabolic pathways. Conversely,
the advantage of EBC is the capture of higher molecular weight,
non-volatile compounds such as peptides and lipids, or even par-
ticles such as viruses trapped in exhaled droplets. There is a wide
range of analysis platforms and computational strategies to inter-
pret the vast amount of information present in exhaled breath,
and many of these platforms are scalable to permit point-of-
care use (22). Exhaled breath, whether collected in gas or liquid
form, represents a novel matrix of human and animal data which
may ultimately serve as a complementary or stand-alone fluid for
disease monitoring.
Of significance to diabetes, non-invasive breath testing rep-
resents an attractive way to test for glycemic control. Current
recommendations by the American Diabetes Association include
multiple daily blood glucose testing in diabetics on insulin, and less
frequent testing in diabetics on oral therapy (23). Current blood
glucose tests are uniformly invasive as they require finger sticks at a
minimum. Potential benefits to breath testing include avoidance of
painful finger sticks, improved compliance with glucose monitor-
ing, and the potential to assess insulin levels, which is currently an
unavailable point-of-care test for most diabetics (24). Better con-
trol and early diagnosis of diabetes through non-invasive means
may help lower morbidity and mortality.
There is a paucity of studies assessing breath biomarkers in
human diabetes, though important efforts have been made. Greiter
et al. were able to distinguish 21 insulin-dependent DM2 subjects
from 26 healthy controls using proton-transfer reaction mass spec-
trometry (PTR-MS) analysis of exhaled gas (25). Though many of
the chemicals were not identified, compounds including acetone,
dimethyl sulfide, isoprene, butanol, and pyridine were identified.
In this study, only acetone was seen in significantly elevated levels
in DM2 subjects on exogenous insulin. Though this is surpris-
ing in DM2 as ketogenesis and acetone production are typically
thought to arise in type-1 diabetes, breath testing may be able
to uncover compounds that challenge the paradigm of diabetes
understanding. Guo et al. sought to correlate human breath ace-
tone concentrations to blood glucose levels (26). In this study,
the correlation was not robust, but the results are promising.
In a study of 16 subjects undergoing an oral glucose tolerance
test, elevated exhaled acetone levels were able to classify diabetics
from non-diabetics, though there were large inter-individual dif-
ferences (27). Goerl et al. studied the breath of 30 subjects with
advanced kidney disease undergoing dialysis (28). In the subset of
subjects with DM2, there was significantly less variation in lon-
gitudinal breath acetone concentrations. Landini and colleagues
studied breath acetone production in patients undergoing med-
ically supervised, calorie-restricted weight loss (29). They showed
that acetone concentrations were elevated in subjects with more
weight loss, presumably reflecting a starvation ketosis rather than
a lack of insulin. Though this study did not specifically assess
diabetics, it supports the principle of acetone evolution in breath
as a reflection of a systemic metabolic process.
Recently, 13C-labeled glucose has been studied as a non-invasive
breath measure of glucose metabolism and insulin resistance in
DM2. Mizrahi et al. demonstrated good correlations between
serum glucose (positive) and insulin (negative) levels to 13C-
glucose breath levels after ingestion of 13C-glucose in healthy
volunteers (30). Another small study correlated breath 13C-glucose
to both urban and rural Asian Indian populations in terms of
insulin resistance, body mass index, and waist circumference (31).
Jetha et al. assessed the role of non-invasive breath 13C-glucose
monitoring in obese children where fears of needle-testing for
glucose levels are high (32). As with prior studies, they found sig-
nificant correlations between the breath and serum tests. These
studies indicate that 13C-glucose tests and acetone concentrations
may be important non-invasive measures of glucose metabolism
in DM2. Whether acetone is important alone or in combination
with other, undiscovered biomarkers remains to be seen.
Related to the MetS and lipid metabolism disorders, few non-
invasive breath studies have been published. The metabolism
of dietary constituents is routinely assessed using exhaled CO2,
though this is a rough marker of lipid metabolism since the metab-
olism of carbohydrates and proteins produce CO2 as well (33, 34).
Indirect evidence of lipid metabolism comes from the breath evo-
lution of lipid peroxidation products such as ethane and pentane
(35), though these may be due to general or airway inflammation
and not to lipid balance. A small study in spontaneously over-
weight mice measured increased exhaled 13CO2 as a marker of
increased lipolysis when the mice were given a thyroid hormone
analog (36). This suggests that CO2 may be a suitable measurement
in certain experimental settings.
BARRIERS TO BREATH ANALYSIS IN THE MetS AND DM2
As with many novel techniques, breath analysis must overcome
several barriers before it is accepted as a part of clinical disease
management. There are certainly success stories such as exhaled
nitric oxide for use in allergies and asthma (37), but the major-
ity of breath tests, particularly for the MetS and DM2, are still
experimental. First, few large-scale studies have been conducted
to validate the findings from smaller studies. This creates substan-
tial problems with technique validation and application across
populations. Next, the validation of individual or groups of bio-
markers (i.e., acetone, glucose, etc.) requires large amounts of
subjects across a range of ethnic and geographic groups. Nomo-
grams for many of the compounds identified in DM2 and the
MetS simply do not exist. In addition, these biomarkers would
need to be assessed longitudinally to account for fluctuations over
time, season, and disease activity. Finally, costs associated with the
development of breath analysis technologies may be high, but as
components become refined and produced to scale, costs would
be expected to decrease (think of standard glucose meters). The
bottom line is that more rigorous experimentation is needed to
validate and advance breath testing in the MetS and DM2.
A DOLPHIN MODEL OF THE HUMANMetS
In this issue and previously, Venn-Watson and colleagues have
reported that Atlantic bottlenose dolphins (Tursiops truncatus)
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are a good model of the human MetS and insulin resistance (38,
39), though accepted definitions of the human MetS vary some-
what from that used by the authors (6–9). In 2011 the authors
published a study where managed dolphins were fed dextrose or
Spanish mackerel (a high-protein, low-carbohydrate meal) (38).
Both meals resulted in sustained hyperglycemia: up to 10 h post-
dextrose and 5 h post-mackerel. Accompanying insulin levels were
also elevated which is similar to the hyperinsulinemia seen in
human DM2 as a result of impaired peripheral insulin metab-
olism (40). The authors’ 2007 work demonstrated that serum
glucose was elevated in fasting dolphins, and that fasting platelets,
gamma-glutamyl transpeptidase, and alkaline phosphatase were
also significantly elevated (39), as may be seen in the human MetS
(41, 42). In the present work, the authors further describe the
metabolic abnormalities among managed and free-ranging dol-
phin populations. In addition to elevated insulin levels, affected
dolphins in the managed group also had elevated glucose, total
cholesterol, HDL-C, VLDL-C, iron, transferrin saturation, and
unmodified adiponectin. These elevations mirror some of the
changes seen in humans with the MetS. Interestingly, managed
dolphins with aberrant blood markers do not appear to have an
elevated mortality, at least not attributed to their metabolic dys-
function (43). The aforementioned body of work suggests that
dolphins share similar physiologic responses with human dia-
betics in reference to fasting and bolus-feeding states, but that
dolphins may utilize diet fluctuations and glycemic changes to
non-pathologic ends. Thus, bottlenose dolphins may be a unique,
phylogenetically close, and accessible model for human diabetes.
Importantly, the bottlenose dolphin model of DM2 and the
MetS has a few key potential applications. First, hyperglycemia in
dolphins appears to be a naturally occurring response to both fast-
ing (39) and post-prandial states (38). As hypothesized, this may
be an adaptive response to stress (e.g., starvation or intermittent
food availability) to keep blood glucose available to the dolphins’
larger brains. Presumably dolphins naturally feed continuously
in food-plentiful environments and therefore maintain more sta-
ble glucose and insulin levels, especially if they have a varied diet
of fish.
As mentioned, the understanding of dietary influences on DM2
and the MetS is essential. Patterns and timing of food consump-
tion have long been recognized as important to weight control
in humans (44, 45), though longitudinal datasets demonstrating
optimal feeding times in diabetic patients are limited to small stud-
ies of fairly short duration. One study that randomized women
with DM2 and polycystic ovarian syndrome to higher breakfast
versus dinner caloric intake for 90 days noted reduced levels of
post-prandial glucose and insulin in patients who ate higher calo-
ries earlier in the day (46). This is supported by other evidence
that consuming high calorie foods with a high glycemic index late
in the day results in higher glucose levels and insulin resistance
(47). Dietary manipulations in managed bottlenose dolphin pop-
ulations could augment existing human data and provide insight
to optimal feeding regimens (both in diet content and timing)
that affect post-prandial glycemic and insulin indices in humans.
Specifically, altering protein and carbohydrate ratios to a group of
dolphins that“behave”like human diabetics without the associated
complications is an attractive prospect.
Another important use of a bottlenose dolphin model for
human disease lies in studying cholesterol fluctuations with
dietary modifications. In the study by Venn-Watson et al. in this
issue, all cholesterol components were elevated in dolphins with
increased glucose and insulin levels. However, they were elevated
in different ways than found in humans with diabetes as the
HDL-C component was disproportionately elevated in dolphins.
In humans, low HDL-C levels often associate with DM2, and
therapy aims to increase the HDL-C component as it is consid-
ered cardio-protective (48). For example, in a case-control study
assessing 113 humans with high HDL-C compared to 212 with
low HDL-C on the incidence of DM2, 1.8 versus 21.7% (high
HDL-C versus low HDL-C) developed DM2 (49). Though dol-
phins develop dyslipidemias as do humans, the mechanisms by
which they develop them and, importantly, the fact they do not
appear to have increased mortality compared to humans, could
shed light into strategies to bolster HDL-C in humans. Further
research into how dolphins maintain high HDL-C in the face of
other metabolic imbalances could prove useful to understanding
human lipid regulation.
As dolphins represent an appealing model of human DM2
and the MetS, and cetacean research should ideally serve the dual
purpose of benefiting animal and human health, researchers may
access both wild and managed dolphins. Two outstanding exam-
ples of successful programs where researchers study wild dolphin
populations include the Mote Marine Laboratory in Sarasota, FL,
USA, and Dolphin Research Australia based in New South Wales.
Free-ranging dolphin research is informative, semi-natural, and
externally valid, though it requires extensive effort (50). Con-
versely, managed dolphins are attractive in that more rigorous
experimentation is possible; however, studies on these populations
may not be applicable to wild dolphins due to differences in life
conditions. Importantly for research, managed dolphins receive
excellent care, have low mortality rates, and have annual survival
rates of 99% (43, 51). Regardless of the population studied, efforts
to optimize cetacean research and maximize data recovery are
paramount. Specifically, one strategy may be utilization of exhaled
breath.
EXHALED BREATH EVALUATION OF DOLPHINS
Though exhaled breath collection from cetaceans has not been
rigorously evaluated, early work assessing exhaled nitric oxide has
demonstrated feasibility (52). Exhaled breath analysis in dolphin
populations has several potential advantages. Given that breath
sampling techniques are non-invasive and do not obstruct the
airway, one would expect breath sampling of dolphins to engen-
der minimal concern. This would facilitate sample collection in
both managed and wild populations. Anatomically, dolphins have
respiratory systems which are separate from their gastrointesti-
nal tracts. This prevents the oropharyngeal and gastrointestinal
contamination of the collected breath which confounds collec-
tion and analysis in humans (53). Uniquely, cetaceans are explo-
sive breathers, exchanging 70–90% of total lung capacity in 0.3 s
(54). The sheer volume of a single dolphin breath is far greater
than many human breaths in aggregate. This breathing behav-
ior leads to rapid gas exchange, quick sample collection, and
minimal contact time with the animals. In addition, bottlenose
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dolphins can hold their breath for about 7 min while diving,
which leads to enrichment of the exhaled gas with endoge-
nous metabolite compounds. Explosive breathing and breath-
holding provide unique advantages to aid in the discovery of
large amounts of exhaled compounds which may directly inform
the design of human breath studies. Furthermore, the limited
genetic variability in dolphins compared to humans would likely
result in lower variability of the metabolic content in the exha-
late. In a proof-of-concept study, we have been able to capture
exhaled breath from bottlenose dolphins, and preliminary analy-
sis indicates a chemical separation of fasting versus non-fasting
animals based on breath constituents such as triglycerides (ten-
tatively identified; unpublished data). As exhaled breath repre-
sents a novel and potentially robust matrix for disease detection,
breath monitoring application in cetaceans appears logical and
important.
In conclusion, DM2 and the MetS are important epidemics
which are predicted to escalate in coming years. As diet is central
to the development of, and potentially the control of, DM2 and
the MetS, a focus on studying dietary influences is key. Cetacean
models of DM2 and the MetS are interesting as Atlantic bot-
tlenose dolphins (T. truncatus) have physio-chemically similar
responses to alterations in diets as do humans, yet they do not
seem to experience increased mortality. Also, the bottlenose dol-
phin is of closer phylogenetic relation to humans than many other
animal models. Key differences in the regulation of HDL-C cho-
lesterol alone are worth intensive scrutiny as novel mechanisms to
bolster HDL-C levels in human diabetics may confer protection
from cardiovascular disease. In addition, studies altering feeding
intensity and diet composition in dolphins may have profound
implications in human disease. The aforementioned advantages
of breath analysis in dolphins present an ideal model for bio-
marker discovery in DM2 and the MetS. Further targeted analysis
of some of the discovered biomarkers may facilitate application of
breath analysis for DM2 monitoring tests in humans. The logical
and ethical use of animal models to complement existing human
data remains an important goal, especially as the cost and lim-
ited scope of human trials can benefit from as much guidance as
possible. As we strive toward obtaining biological samples using
the least invasive methods, exhaled breath as a novel matrix to
study in both animals and humans emerges as a viable and inter-
esting option. Though we are not ready to use exhaled breath
analysis in lieu of invasive blood tests, this reality may not be
far off.
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